Dr. Ren Hua got his Bachelor of Medicine from Shanghai Medical College, Fudan University in 1997, a Master's degree from Peking Union Medical College in 2004, and a Ph.D. in 2010. He has served as a resident physician, attending physician, and deputy chief physician in the Department of Radiation Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences since 1997. From 2008 to 2010, he conducted clinical research on stereotactic radiation therapy at Houston Methodist Hospital, Weill Cornell Medical College. From 2016 to 2021, he was posted to Shenzhen Hospital of the Cancer Hospital Chinese Academy of Medical Sciences, responsible for hospital medical system setup and served as the Director of the medical affair department. From 2021 to 2024, he served as the Chief Medical Officer at Shenzhen New Frontier United Family Hospital. He received several awards, including the "China Oncology Star of Tomorrow" (2nd session) by the Oncology Society of the Chinese Medical Association in 2013, the "Shenzhen Practical Clinical Medical Talent" (Category II) by the Shenzhen Health Commission in 2020, and the "Shenzhen Longgang Talent" (Category A) by Longgang District.

Oncology, Radiation Therapy, Immunotherapy, Hospital Management

Bachelor's Degree in Clinical Medicine, Shanghai Medical University, 1997

Master's Degree, Chinese Academy of Medical Sciences/Peking Union Medical College, 2004

Doctorate Degree, Chinese Academy of Medical Sciences/Peking Union Medical College, 2010

Research Coordinator/Visiting Scholar, Houston Methodist Hospital , Weill Cornell Medicine, USA (Dec. 2008 - Jan. 2010)

Resident Physician, Department of Radiotherapy, Chinese Academy of Medical Sciences Cancer Hospital, 1997.9 - 2005.10

Attending Physician, Department of Radiotherapy, Chinese Academy of Medical Sciences Cancer Hospital, 2005.10 - 2016.10

Deputy Chief Physician, Department of Radiotherapy, Chinese Academy of Medical Sciences Cancer Hospital, 2016.10 - 2021.2

Director of Medical Affair Department , Shenzhen Branch of Chinese Academy of Medical Sciences Cancer Hospital, 2016.4 - 2021.2

Chief Medical Officer, Shenzhen new frontier United family Hospital, Feb. 2021 -Dec. 2024

Clinical Associate Professor, Southern University of Science and Technology, Jul 2020-Jul. 2025

2013 "Star of Tomorrow in Chinese Oncology" (the 2nd Session) ,Oncology society of the Chinese Medical Association

2020 "Shenzhen Practical Clinical Medical Talents" (Type II) , Shenzhen Municipal Health Commission

"Shenlong Talents" (Type A) , Longgang District of Shenzhen 

Editorial Board Member of Electronic Journal of Liver Cancer,   Peer Reviewer of China Medical Herald

First Author/ Corresponding Author

1 Platelet-to-lymphocyte ratio is associated with prognosis in patients with Corona Virus Disease-19. J Med Virol. 2020; Sep;92(9):1533-1541

2 Comparison of the efficacy and safety of PD-1 inhibitor monotherapy and combined chemotherapy/targeted therapy for advanced malignancies Hou Lina et al. International Journal of Oncology April 2020, Volume 47, Issue 4, 193-197   (chinese)

3 Comparative study of VMAT and IMRT models based on empirical planning for predicting IMRT dose distribution in prostate Bi Suyan et al. Chinese Journal of Radiation Oncology February 2021, Volume 30, Issue 2, 164-169  (chinese)

4 PD-1 restrains IL-17A production from γδ T cells to modulate acute radiation-induced lung injury. Transl Lung Cancer Res. 2021 Feb;10(2):685-698.

5 ATF2-Induced Overexpression of lncRNA LINC00882, as a Novel Therapeutic Target, Accelerates Hepatocellular Carcinoma Progression via Sponging miR-214-3p to Upregulate CENPM. Ren H,et al. Front Oncol. 2021 Aug 27;11:714264.

Co-Author

1 Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.Lancet Oncol

. 2019 Mar;20(3):352-360

2 Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China.

J Clin Oncol. 2020 Nov 1;38(31):3604-3614

3 Switching-on Prodrugs Using Radiotherapy.Nat Chem. 2021 Aug 1; 13(8): 805–810.

4 Phase 2 Study of Adjuvant Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.Hepatology. 2021 Nov;74(5):2595-2604.

5 Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial.JAMA Netw Open. 2021 Nov 1;4(11):e2136116.

6 Postoperative chemoradiotherapy with capecitabine and oxaliplatin vs.capecitabine for pathological stage N2 rectal cancer.  Chin J Cancer Res. 2024 Oct 30;36(5):577-586.